Neuren Pharmaceuticals Limited
NURPF
Other OTC16.10
USD
- -
- -
ISIN
NZNEUE0001S8
Return %
Stock
S&P500
1Y
26.37
18.65
3Y
114.95
71.44
5Y
820.00
70.60
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jonathan Charles Pilcher
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Suite 1.01, 117 Camberwell Road Hawthorn East VIC Australia 3123
- IPO Date
- Nov 4, 2009
- Website
- neurenpharma.com
- Similar Companies
- Business
- Neuren Pharmaceuticals Limited is a biopharmaceutical company primarily engaged in the development and commercialization of innovative therapeutic products for the treatment of neurological and neurodevelopmental disorders. The company’s core products include drug candidates addressing conditions such as fragile X syndrome, Rett syndrome, and other neurodevelopmental and neurodegenerative diseases; key product candidates focus on peptide compounds like trofinetide and NNZ-2591. Neuren Pharmaceuticals develops, licenses, and markets these pharmaceutical compounds primarily across global markets, including North America, Europe, and Oceania. Established in 1998, the company is headquartered in Melbourne, Australia. In the last one to two years, Neuren Pharmaceuticals has made significant strategic advancements including advancing late-stage clinical trials for trofinetide in fragile X syndrome and Rett syndrome. The company has also strengthened its commercial partnerships to support the potential launch and marketing of its lead products in key territories. Additionally, Neuren has expanded its development pipeline and research collaborations to broaden its neurological disorder treatment portfolio. These efforts reflect a strategic shift toward commercialization and global market expansion of its proven drug candidates. Neuren operates principally in the pharmaceutical and biotechnology industry segments with a focus on specialty pharmaceuticals targeting rare and underserved neurological conditions. Its primary customers include healthcare providers, research institutions, and ultimately patients needing innovative neurological therapies. The company operates subsidiaries and collaborates with international partners to facilitate clinical development and product commercialization. Overall, Neuren Pharmaceuticals Limited is a specialized biopharma company focused on developing novel peptide-based therapies for neurodevelopmental diseases with an increasing emphasis on global partnerships, late-stage clinical development, and preparation for market introduction of its flagship products. This description reflects Neuren Pharmaceuticals’ latest business focus, key products and services, strategic changes, and geographic and operational footprint as publicly available information as of December 2025.
Company News
Neuren Pharmaceuticals Limited (NURPF) Q2 2026 Earnings Call Transcript
Hyperion DeFi (NASDAQ:HYPD) versus Neuren Pharmaceuticals (OTCMKTS:NURPF) Critical Survey
Neuren Pharmaceuticals (OTCMKTS:NURPF) Stock Price Down 13.5% – Should You Sell?
Neuren Pharmaceuticals Limited (NURPF) Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 Transcript